All In Biotech

Drug Trial Radar · NCT06362746

Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism

Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the Efficacy and Safety of a Single Bolus Administration of Non-immunogenic Recombinant Staphylokinase in Patients With Intermediate High-risk Pulmonary Embolism (FORPE-2)

Last checked: Nov 20, 2026Latest source record: Dec 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 486 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

486

Planned (sponsor's estimate)

Start

May 23, 2024

Primary completion

Jun 1, 2028

Study completion Dec 1, 2028

Sponsor

Lead sponsor
Supergene, LLCIndustry
Sponsor type
Industry
First posted
Apr 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Objective: to evaluate the efficacy and safety of the non-immunogenic recombinant staphylokinase with its single bolus administration in comparison with placebo in normotensive patients with intermediate high-risk pulmonary embolism (PE)

Conditions

  • Pulmonary Embolism

Interventions

  • Non-immunogenic recombinant staphylokinaseDrug

    15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds

  • PlaceboDrug

    15 mg of placebo reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of death from any cause or hemodynamic collapse or recurrent PETime frame: within 30 days

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Belgorod Regional Clinical Hospital of St. Joseph

    Belgorod, Russia · Recruiting

  • Kuzbass Cardiology center

    Kemerovo, Russia · Recruiting

  • Center of Neurology and Cardiology

    Kirov, Russia · Recruiting

  • Regional Clinical Hospital №2

    Krasnodar, Russia · Recruiting

  • Lipetsk City Hospital No. 4 "Lipetsk-Med"

    Lipetsk, Russia · Recruiting

  • F.I. Inozemtsev City Clinical Hospital

    Moscow, Russia · Recruiting

  • Moscow Multidisciplinary Clinical Center "Kommunarka"

    Moscow, Russia · Recruiting

  • S.S. Yudin City Clinical Hospital

    Moscow, Russia · Recruiting

  • V.M. Buyanov City Clinical Hospital

    Moscow, Russia · Recruiting

  • S.P. Botkin City Clinical Hospital

    Moscow, Russia · Recruiting

  • N.A. Semashko Nizhny Novgorod Regional Clinical Hospital

    Nizhny Novgorod, Russia · Recruiting

  • N.N. Burdenko Penza Regional Clinical hospital

    Penza, Russia · Withdrawn

  • G.A. Zakharyin Clinical hospital №6

    Penza, Russia · Recruiting

  • City Clinical Hospital №4

    Perm, Russia · Withdrawn

  • City Hospital No. 26

    Saint Petersburg, Russia · Recruiting

  • City Hospital No. 15

    Saint Petersburg, Russia · Recruiting

  • V.P. Polyakov Samara Regional Clinical Cardiology Dispensary

    Samara, Russia · Recruiting

  • Tomsk regional cilinical hospital

    Tomsk, Russia · Recruiting

  • Tver Regional Clinical Hospital

    Tver', Russia · Recruiting

  • Ufa Emergency City Hospital

    Ufa, Russia · Recruiting

  • City Clinical Hospital of Emergency medicine №25

    Volgograd, Russia · Recruiting

  • RZD Medicine hospital

    Barnaul, Altayskiy Kray, Russia · Recruiting

  • V.F. Dolgopolov Vyselki Central District Hospital

    Vyselki, Krasnodarskiy Kray, Russia · Recruiting

  • Asinovskaya District Hospital

    Asino, Tomsk Oblast, Russia · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.